Thanks XOC! Very eye opening. Brilacidin will have a global impact and make more money for multiple indications in addition to the already established ABSSI.
I wonder why Cellceutix stopped pursuing this widespread (and lucrative) indication, and yet recently picked up HS and UP. I wonder if they're trying to cultivate a "GI" theme, for initial marketing purposes.
That presentation is from 2008; the article in another post is from 2009. This is 2015...are we still testing B for TB...or was that just a failed drug or a dropped for lack of money drug?
News 
Market Data 
Discover 
